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Vav1 is a Rho/Rac guanine nucleotide exchange factor 
primarily expressed in hematopoietic cells. In this study, we 
investigated the potential role of Vav1 in osteoclast (OC) 
differentiation by comparing the ability of bone marrow 
mononuclear cells (BMMCs) obtained from Vav1-deficient 
(Vav1−/−) and wild-type (WT) mice to differentiate into mature 
OCs upon stimulation with macrophage colony stimulating 
factor and receptor activator of nuclear kappa B ligand in vitro. 
Our results suggested that Vav1 deficiency promoted the 
differentiation of BMMCs into OCs, as indicated by the 
increased expression of tartrate-resistant acid phosphatase, 
cathepsin K, and calcitonin receptor. Therefore, Vav1 may 
play a negative role in OC differentiation. This hypothesis was 
supported by the observation of more OCs in the femurs of 
Vav1−/− mice than in WT mice. Furthermore, the bone status 
of Vav1−/− mice was analyzed in situ and the femurs of 
Vav1−/− mice appeared abnormal, with poor bone density 
and fewer number of trabeculae. In addition, Vav1-deficient 
OCs showed stronger adhesion to vitronectin, an v3 integrin 
ligand important in bone resorption. Thus, Vav1 may inhibit 
OC differentiation and protect against bone resorption. [BMB 
Reports 2019; 52(11): 659-664]
INTRODUCTION
Vav proteins are Dbl family guanine nucleotide exchange 
factors (GEFs) that activate Rho family GTPases by stimulating 
the release of GDP to allow GTP binding. There are three 
members of the Vav protein family, Vav1, Vav2, and Vav3. 
Vav1 is expressed exclusively in hematopoietic cells (1), 
whereas Vav2 and Vav3 are expressed ubiquitously. Vav 
proteins are involved in essential cellular processes such as 
differentiation, proliferation, cytoskeletal organization, and 
vesicle trafficking. In addition, these proteins play an essential 
role in the coupling of 2 integrin to Rho GTPases and regulate 
multiple integrin-induced events in leukocyte adhesion, 
migration, and phagocytosis (2, 3). Vav proteins are activated 
by growth factor receptors, chemokine receptors and integrins, 
and regulate multiple cellular processes such as osteoclast 
(OC) differentiation via the activation of Rho GTPases (4). 
Although Vav proteins share redundant functions, they also 
exhibit unique, isoform-specific roles. Vav1 regulates actin 
polymerization, cytoskeletal organization, adhesion, migration, 
and phagocytosis in hematopoietic cells. Vav1 is also required 
for optimal spreading and regulation by IIb3 integrin (5), and 
upregulates 41-mediated T lymphocyte adhesion (6, 7) and 
1 integrin-mediated adhesion in dendritic cells (8).
Bone homeostasis is critical for the maintenance, repair and 
remodeling of bones, and depends on the balance between 
bone formation by osteoblasts and bone breakdown by OCs. 
OCs are a type of bone cell responsible for breaking down 
bone tissue via a process termed resorption, which occurs 
through physical association between OCs and the bone 
matrix (9, 10). OCs differentiate from the hematopoietic 
monocyte/macrophage lineage and are formed by the fusion of 
mononuclear OC precursor cells into multinucleate cells with 
abundant cytoplasmic azurophilic granules (11, 12). OCs can 
be produced from bone marrow mononuclear cells (BMMCs) 
in vitro by several cytokines, such as macrophage colony 
stimulating factor (M-CSF) and receptor activator of nuclear 
factor kappa B (NF-B) ligand (RANKL) (13). OCs must tightly 
adhere to the bone surface to form a sealing zone which 
facilitates bone resorption (14). The binding of integrins to 
their corresponding ligands plays an important role in bone 
recognition by OCs. The transmembrane integrin v3 is the 
most abundant integrin in OCs (15), and several studies have 
reported that v3 integrin mediates the adhesion of OCs to 
bone surfaces.
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Fig. 1. TRAP-positive OC formation was increased in Vav1−/−
mice. (A) Total RNA was prepared from the OCs of WT and 
Vav1−/− mice and the absence of Vav1 mRNA was verified by 
RT-PCR (n = 6). (B) Vav1 protein deficiency in the OCs was 
confirmed by western blotting using an anti-Vav1 polyclonal 
antibody (n = 3). RNA and protein samples from Rac2−/− OCs 
were used as controls. (C, D) BMMCs were differentiated in the 
presence of 30 ng/ml M-CSF and 50 ng/ml RANKL, and 
TRAP-positive multinucleated OCs were counted (n = 10). (E) 
TRAP-positive OCs differentiated from littermate mice were 
counted (n = 3), *P ＜ 0.05 and **P ＜ 0.01.
Fig. 2. OC-specific markers and TRAP activity were increased in 
Vav1−/− mice. Expression level of mRNA of TRAP (A), CTSK (B), 
CTR (C), and DC-STAMP (D) in OCs was measured by qRT-PCR 
(n = 5). (E) TRAP activity in OCs was determined using 
p-nitrophenyl phosphate as the substrate (n = 3), *P ＜ 0.05 and 
**P ＜ 0.01.
In this study, we explored the possible role of Vav1 in OC 
differentiation and bone resorption using Vav1-deficient 
(Vav1−/−) mice. BMMCs differentiate into OC precursors in 
the presence of M-CSF in vitro, and subsequently develop into 
mature OCs in the presence of M-CSF and RANKL (16). 
Vav1−/− mice were used to evaluate whether Vav1−/− 
BMMCs differed from wild-type (WT) BMMCs in their ability 
to differentiate into OCs in vitro by measuring various 
OC-specific markers, such as tartrate-resistant acid 
phosphatase (TRAP), cathepsin K (CTSK), calcitonin receptor 
(CTR), and dendritic cell-specific transmembrane protein 
(DC-STAMP). We demonstrated that Vav1 suppressed OC 
differentiation, as indicated by the increased expression levels 
of OC markers in differentiating Vav1−/− cells in vitro. 
Consistently, TRAP expression was more apparent in the 
femoral bones of Vav1−/− mice than in those of WT mice. We 
observed abnormalities in the bone mineral density and 
number of trabeculae in the femurs of Vav1−/− mice in vivo. 
This study reveals the important role of Vav1 in the prevention 
of bone resorption by suppressing OC differentiation.
RESULTS 
Vav1 suppresses the differentiation of TRAP-positive 
multinucleated cells
We investigated the role of Vav1 in OC differentiation and 
bone absorption by comparing Vav1−/− and WT mice. First, 
we verified the disruption of Vav1 gene expression in the OCs 
of the Vav1−/− mice used in this study (Fig. 1A, B). OC 
precursors were defined as the cells resulting from a 4-day 
culture with M-CSF, while mature OCs were defined as the 
cells obtained from an additional 4 days of culture with M-CSF 
and RANKL. TRAP activity is an important marker of mature 
and functional OCs. In the OC precursors, no noticeable 
differences were observed in the TRAP level between the 
Vav1−/− and WT cells (data not shown). However, as the OC 
precursors differentiated into mature OCs the number of 
TRAP-positive multinucleated OCs was significantly higher in 
the Vav1−/− cells than in the WT cells (Fig. 1C, D), while 
heterozygous Vav1＋/− mice produced intermediate levels of 
TRAP-positive OCs (Fig. 1E). This dose-dependent production 
of TRAP-positive OCs suggests that Vav1 suppressed OC 
differentiation. However, the suppressive role of Vav1 seems 
to be opposite to the effect of Vav3 on OC differentiation 
reported previously (17). The mechanisms underlying these 
opposing roles of Vav1 and Vav3 in OC differentiation are not 
yet understood.
Vav1 suppresses the expression of osteoclastogenic makers 
We determined the mRNA levels of osteoclastogenic makers 
in WT and Vav1−/− OCs. In addition to TRAP, CTSK, CTR, 
and DC-STAMP are essential for bone resorption (18, 19) and 
their expression levels increase during osteoclastogenesis. 
Quantitative RT-PCR analysis showed that the mRNA 
expression of these markers was significantly higher in 
Vav1−/− OCs compared to WT OCs (Fig. 2A-D). Consistent 
with the increase in the number of TRAP-positive OCs, the 
enzymatic activity of TRAP was also higher in Vav1−/− OCs 
than in WT OCs, confirming the negative effect of Vav1 on 
OC differentiation (Fig. 2E).
Vav1 suppresses v3-mediated adhesion of OCs
The binding of integrins to their corresponding ligands plays 
an important role in the recognition of bone by OCs (3). 
Integrin v3 is the most abundant integrin in OCs (14). Vav 
proteins are known to control integrin-mediated cell adhesion 
through “inside-out” signaling. However, the roles of Vav1 in 
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Fig. 3. Adhesion of OC precursors to vitronectin was increased in 
the absence of Vav1. The ability of OC precursors to adhere to 
vitronectin was determined in the presence of M-CSF and RANKL 
for 10 and 60 min (A), and the number of adhered cells was 
counted and plotted as a histogram (B) (n = 3), *P ＜ 0.05.
Fig. 4. Vav1 deletion leads to poor bone density in vivo. (A) 
Microcomputed tomography of the femurs of WT and Vav1−/−
mice (6-wk-old male mice, n = 4 per group). (B) Trabecular 
bone volumes of WT and Vav1−/− mice were compared using 
quantitative CT. (C-E) Trabecular bone parameters of WT and 
Vav1−/− mice were compared. (F) TRAP-positive cells in the 
femurs of 24-wk-old male mice were detected (n = 3 per group). 
(G) The number of TRAP-positive cells in selected femur fields 
was counted (n = 3), *P ＜ 0.05 and **P ＜ 0.01.
integrin v3-mediated cell adhesion remain unclear. 
Vitronectin is a glycoprotein that binds to integrin v3 as it 
contains an Arg-Gly-Asp sequence, a specific integrin v3 
binding site. Therefore, we examined whether Vav1 was 
involved in integrin v3-mediated adhesion by comparing the 
binding ability of Vav1−/− and WT OC precursors on 
vitronectin-coated plates. Following the incubation of OC 
precursors on vitronectin-coated plates for 10 and 60 min, the 
number of adhered cells was counted and plotted as a histogram 
(Fig. 3). The Vav1−/− OC precursors exhibited greater 
adherence to the vitronectin-coated plates than the WT cells. 
We also determined actin ring formation by Alexa-phalloidin 
staining, with Vav1−/− OCs showing higher levels of actin ring 
formation than the WT cells (Supplementary Fig. 1). These 
results indicate that Vav1 suppresses the v3-mediated 
adhesion of OCs, presumably resulting in the attenuation of 
bone resorption activity. 
Vav1 deficiency reduces bone volume fraction and number of 
trabeculae in femurs 
As OCs are known to be involved in bone resorption, we 
compared the bone densities of Vav1−/− and WT mice using 
CT. The femurs of Vav1−/− mice appeared less dense than 
those of WT mice (Fig. 4A). To confirm this observation, the 
ratio of trabecular bone volume to total bone volume (BV/TV, 
%), trabecular thickness (Tb.Th, m), trabecular separation 
(Tb.Sp, m), and the number of trabeculae (Tb.N, mm−1) were 
assessed. Trabeculae are composed of bone cells and 
collagenous tissue, and are an important skeletal element that 
supports the framework of organs and body. The BV/TV ratio 
is an important parameter for evaluating the microstructure of 
the trabecular bone (20). Vav1−/− mice showed significantly 
lower BV/TV, Tb.Th, and Tb.N than WT mice (Fig. 4B-E), 
demonstrating that Vav1 prevents OC-mediated reductions in 
bone mass.
Bones of Vav1−/− mice contain more TRAP-positive cells 
than those of WT mice 
As the results obtained with OCs in vitro suggested that Vav1 
suppresses OC differentiation, we examined the effects of 
Vav1 on OC formation in vivo. We compared the number of 
TRAP-positive cells in the bone sections obtained from 
Vav1−/− and WT mice. Consistent with the in vitro results, the 
femoral bone sections of Vav1−/− mice had almost twice as 
many TRAP-positive cells than those of WT mice (Fig. 4F, G), 
confirming the suppression of OC differentiation by Vav1 in 
vivo.
DISCUSSION
Vav family GEFs are expressed as three isoforms, with Vav3 
being the most abundant in OCs (17). Vav3 has been shown to 
stimulate OC differentiation and bone resorption by enhancing 
the affinity of integrin v3 for vitronectin (17). Vav3-deficient 
OCs display defective resorption activity due to impaired 
signaling downstream of the M-CSF receptor and v3 integrin. 
As a result, the bones of Vav3-deficient mice exhibit increased 
density.
In this study, we evaluated the role of Vav1 in OC 
differentiation. Surprisingly, Vav1 had the opposite effect of 
Vav3 by suppressing OC differentiation and bone resorption. 
To clarify the suppressive effect of Vav1 on OC differentiation, 
we determined the expression and activation levels of kinases 
known to be involved in OC differentiation, such as 
mitogen-activated protein kinases (MAPKs) and Akt (21-23). 
RANK signaling is initiated by cytoplasmic tumor necrosis 
factor receptor-associated factors that trigger the activation of 
signaling cascades downstream of these kinases (24, 25). 
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MAPKs play important roles in osteoclastogenesis and the 
expression of MAPKs has been shown to increase in response 
to RANKL in RAW 264.7 cells (21). Osteoclastogenesis is 
regulated by the balance between extracellular signaling- 
regulated kinase (ERK) and p38 MAPK signaling. ERK 
inhibitors enhance OC differentiation, whereas p38 MAPK 
inhibitors suppress OC differentiation (21). In this study, the 
activation of MAPKs by M-CSF and RANKL was inconsistent 
and the activation of MAPKs and Akt was unimpaired in 
Vav1−/− OCs (data not shown). These results were consistent 
with our finding that MAPKs signaling was unaltered in the 
neutrophils of Vav1−/− mice (data not shown).
The tentative targets for Vav1 are Rac1, Rac2, and RhoG 
(26), whereas Vav2 and Vav3 have a higher activity towards 
RhoA, RhoB, and RhoG (4, 27). RANKL selectively activates 
Rac1; hence, Rac1 may be a key regulator of OC 
differentiation via the activation of NF-B (28). Vav1 is known 
to preferentially activate Rac1 (26, 29); thus, we investigated 
Rac activation in Vav1−/− OCs using an affinity precipitation 
assay for Rac-GTP (22). The levels of active Rac-GTP 
decreased with OC differentiation; however, no difference in 
Rac activation was observed between WT and Vav1−/− OCs 
(data not shown). These results were inconsistent with 
previous studies, which showed that RANKL selectively 
activates Rac1 but not Rac2, and that Rac1 selectively 
regulates OC differentiation (28, 30). To determine the GEF 
role of Vav1 on hematopoietic-specific Rac2, we differentiated 
the BMMCs of Rac2−/− mice (31) into OCs. The number of 
OCs in Rac2−/− cells decreased to 40% of the number in WT 
cells, whilst, it increased in Vav1−/− cells (data not shown). 
We expected that Vav1 and Rac2 would exert similar effects 
on OC differentiation; however, Vav1 suppressed OC 
differentiation whilst Rac2 was essential. This suggests that 
Vav1 is not an upstream regulator of Rac2-mediated OC 
differentiation. 
Currently, there is no clear explanation for the opposing 
activities of Vav1 and Vav3 in OC differentiation and bone 
resorption. We speculate that Vav1 may co-exist with Vav3 
and share common target molecules in OCs, and that Vav1 
may inhibit or counterbalance Vav3-mediated OC differentiation 
by competitively inhibiting Vav3 binding to their common 
target molecules in response to “outside-in” signaling from 
extracellular signals. Vav1 deficiency may increase the effects 
of Vav3 on OC differentiation and bone resorption as 
observed in the femurs of Vav1−/− mice. Rho-GEF kalirin has 
been reported to play a similar role to Vav1 in maintaining 
bone mass by controlling OC differentiation. Deletion of 
kalirin results in the decrease in the cortical bone mass of mice 
(32). Genomic studies have suggested that the function of Vav 
isoforms may have co-evolved with tyrosine kinase pathways 
to convert extracellular signals into biological responses in a 
competitive manner (33). 
In summary, this study demonstrates that Vav1 suppresses 
OC differentiation, as shown by the increased potential of 
Vav1−/− BMMCs to differentiate into OCs than WT BMMCs. 
This was confirmed by the increased number of mature 
TRAP-positive OCs in the low density femoral bones of 
Vav1−/− mice. Moreover, Vav1 inhibited the adhesion of OC 
precursors to vitronectin. Therefore, Vav1 may prevent bone 
resorption by inhibiting the interaction between OCs and bone 
tissues via integrins in order to maintain bone mass. 
MATERIALS AND METHODS
Reagents
M-CSF and RANKL were purchased from PeproTech (London, 
UK). Phosphate-buffered saline (PBS), –minimum essential 
medium (-MEM), and fetal bovine serum (FBS) were obtained 
from HyClone (Logan, UT). PCR primers were procured from 
Bioneer (Daejeon, Korea). All other chemicals were purchased 
from Sigma (St, Louis, MO).
Mice
Vav1−/− mice were generated previously (34) and the 
C57BL/6J mice used as the WT control were purchased from 
Jackson Laboratory (Bar Harbor, ME). Mice were housed under 
pathogen-free conditions in the animal facility of Inha 
University. All procedures were conducted in accordance with 
the institutional guidelines approved by the Animal Care and 
Use Committee of Inha University (INHA 161214-465). To 
isolate bone marrow cells, mice were sacrificed by cervical 
dislocation and every effort was made to minimize their 
suffering.
Osteoclast differentiation from bone marrow cells
Bone marrow cells were prepared from 6 to 8-wk-old male 
mice and cultured overnight in -MEM supplemented with 
10% FBS and 10 ng/ml M-CSF. Non-adherent cells were 
separated and cultured continuously with 30 ng/ml M-CSF for 
more 3 days to induce differentiation into OC precursors. 
These cells were cultured for an additional 4 days in the 
presence of 30 ng/ml M-CSF and 50 ng/ml RANKL. The 
formation of multinucleated functional OCs was assessed by 
counting the number of TRAP-positive cells containing more 
than three nuclei.
TRAP staining
We stained TRAP-positive cells using a Leukocyte Acid 
Phosphatase Assay kit according to the manufacturer’s 
instructions. Briefly, cells were washed with PBS and fixed 
using a fixative solution containing citrate solution, acetone, 
and 37% formaldehyde. Fixed cells were treated with TRAP 
staining solution for 60 min at 37oC and washed twice with 
water. After counterstaining with hematoxylin, the number of 
TRAP-positive cells containing three or more nuclei was 
counted.
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Analysis of TRAP activity
TRAP enzyme activity was determined as described previously 
(35). Cells were incubated with 10 mM sodium tartrate and 5 
mM p-nitrophenyl phosphate in 50 mM citrate buffer (pH 4.5) 
for 30 min at 37oC. The enzyme reaction was then terminated 
with 0.1 N NaOH. Absorbance was measured at 405 nm using 
a VersaMax microplate reader (Molecular Devices, Sunnyvale, 
CA) equipped with SoftMax software. 
RT-PCR and quantitative PCR 
Total RNA was extracted from the OCs using TRI reagent 
(MRC, Cincinnati, OH) according to the manufacturer’s in-
structions, and then reverse transcribed according to the 
protocol provided by Takara Bio (Japan). The PCR amplifica-
tion of Vav1 mRNA was performed using the following 
primers; forward, 5’-GAC GAA GAT ATT TAC AGT GG-3’ and 
reverse, 5’-GCT TAT CAT ACT CTG TCA TC-3’. Quantitative 
real time (qRT)-PCR was carried out on an Applied Biosystems 
StepOne unit (Foster City, CA) with SYBR Green PCR Master 
Mix (Toyobo, Japan) and the following primers (forward and 
reverse, respectively): TRAP, 5’-ACG GCT ACT TGC GGT TTC 
A-3’ and 5’-TCC TTG GGA GGC TGG TCT T-3’; CTSK, 
5’-GAA GAA GAC TCA CCA GAA GCA G-3’ and 5’-TCC 
AGG TTA TGG GCA GAG ATT-3’; CTR, 5’-TGC TGG CTG 
AGT GCA GAA ACC-3’ and 5’-GGC CTT CAC AGC CTT CAG 
GTA C-3’; DC-STAMP, 5’-TCCTCCATGAACAAACAGTTCCA 
A-3’ and 5’-AGACGTGGTTTAGGAATGCAGCTC-3’; GAPDH, 
5’-CCT TCC GTC CTA CCC C-3’ and 5’-CCC AAG ATG CCC 
TTC ATG-3’ (35). Amplification data were analyzed using the 
sequence detection software provided by Applied Biosystems.
Adhesion assay
OC precursors were seeded in 48-wells plates coated with 10 
g/ml vitronectin (R&D Systems, Minneapolis, MN) for 10 and 
60 min at 37oC. Unattached cells were rinsed with PBS, 
stained with Diff-Quick solutions (Thermo, Rockford, IL), 
observed under the Axioskop2 Plus microscope (Carl Zeiss, 
Oberkochen, Germany), and then the number of adhered cells 
was counted.
Histology and microcomputed tomography (CT) analysis
The femurs of 6-wk-old male mice were fixed with 10% 
formalin, decalcified with 10% EDTA, dehydrated, embedded 
in paraffin, and sliced into 5 m sections. The sections were 
either stained for TRAP or hematoxylin and eosin. The 
trabecular microarchitecture of the distal femoral metaphysis 
was determined using SkyScan CT (Brucker, Belgium) at 80 
kV, 80 A, and a 6.5-m voxel size. Cortical bone parameters 
such as, BV/TV, Tb.Th, Tb.Sp, and Tb.N were analyzed by 
CT at 3000 ms per projection (500 projections in total) (36).
Western blot analysis
Lysates from OCs were prepared as described previously (37) 
and electrophoresed on 10% SDS-PAGE. The resolved 
proteins were transferred onto a PVDF membrane (Millipore, 
Bedford, MA) and probed with an antibody to Vav1 (C-14; 
Santa Cruz Biotech. Dallas, TX). Immunoblots were developed 
using ECL reagent (Thermo). 
Statistical analyses
Two-tailed Student’s t-test (paired) was performed using 
Microsoft Excel (Redmond, WA). Data are expressed as the 
mean ± standard deviation (SD) and p values of P ＜ 0.05 
were considered significant.
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